Skip to main content
. 2022 May 27;23:132. doi: 10.1186/s12931-022-02053-2

Table 1.

Association between clinical characteristics and EGFR and ALK status in the testing cohort

Characteristics EGFR ALK
Wild-type Mutant-type P value Wild-type Mutant-type P value
Age, years 0.390  < 0.001
 Median 61 60 61 54
 Range 23–88 31–86 23–88 27–81
Gender  < 0.001 0.337
 Female 495 (72.37) 321 (41.15) 783 (56.01) 33 (50.00)
 Male 189 (27.63) 459 (58.85) 615 (43.99) 33 (50.00)
Smoking history  < 0.001 0.121
 Never-smoker 345 (50.51) 635 (81.41) 930 (66.57) 50 (75.76)
 Ever-smoker 338 (49.49) 145 (18.59) 467 (33.43) 16 (24.24)
Pathology  < 0.001 0.036
 Adenocarcinoma 585 (85.53) 753 (96.54) 1273 (91.06) 65 (98.48)
 Non-adenocarcinoma 99 (14.47) 27 (3.46) 125 (8.94) 1 (1.52)
AFP 0.104 1.000
 Negative 538 (98.18) 642 (99.23) 1126 (98.69) 54 (100.00)
 Positive 10 (1.82) 5 (0.77) 15 (1.31) 0 (0.00)
CEA 0.014 0.060
 Negative 341 (50.52) 342 (44.07) 645 (46.54) 38 (58.46)
 Positive 334 (49.48) 434 (55.93) 741 (53.46) 27 (41.54)
CA125  < 0.001 0.164
 Negative 319 (48.41) 458 (59.87) 748 (54.96) 29 (46.03)
 Positive 340 (51.59) 307 (40.13) 613 (45.04) 34 (53.97)
CA19-9 0.031 0.530
 Negative 493 (75.61) 610 (80.37) 1055 (78.32) 48 (75.00)
 Positive 159 (24.39) 149 (19.63) 292 (21.68) 16 (25.00)
CA15-3 0.195  < 0.001
 Negative 451 (75.04) 542 (78.10) 962 (77.64) 31 (55.36)
 Positive 150 (24.96) 152 (21.90) 277 (22.36) 25 (44.64)
FERR  < 0.001 0.135
 Negative 210 (55.56) 289 (68.16) 471 (61.65) 28 (73.68)
 Positive 168 (44.44) 135 (31.84) 293 (38.35) 10 (26.32)
CA72-4 0.010 0.209
 Negative 289 (72.43) 369 (79.87) 630 (76.83) 28 (68.29)
 Positive 110 (27.57) 93 (20.13) 190 (23.17) 13 (31.71)
PSA 0.610 0.711
 Negative 262 (91.93) 165 (93.22) 403 (92.22) 24 (96.00)
 Positive 23 (8.07) 12 (6.78) 34 (7.78) 1 (4.00)
FPSA 0.436 1.000
 Negative 272 (95.44) 166 (93.79) 414 (94.74) 24 (96.00)
 Positive 13 (4.56) 11 (6.21) 23 (5.26) 1 (4.00)
SCC  < 0.001 0.178
 Negative 472 (76.62) 636 (90.34) 1063 (84.23) 45 (77.59)
 Positive 144 (23.38) 68 (9.66) 199 (15.77) 13 (22.41)
CYFRA 21-1  < 0.001 0.137
 Negative 216 (35.64) 332 (47.91) 519 (41.75) 29 (51.79)
 Positive 390 (64.36) 361 (52.09) 724 (58.25) 27 (48.21)
NSE 0.034 0.472
 Negative 212 (44.17) 268 (50.85) 460 (47.92) 20 (42.55)
 Positive 268 (55.83) 259 (49.15) 500 (52.08) 27 (57.45)
TTF-1  < 0.001 0.145
 Negative 129 (20.48) 14 (2.04) 140 (11.13) 3 (5.08)
 Positive 501 (79.52) 673 (97.96) 1118 (88.87) 56 (94.92)
Napsin A  < 0.001 0.401
 Negative 121 (28.67) 19 (5.23) 135 (18.10) 5 (12.82)
 Positive 301 (71.33) 344 (94.77) 611 (81.90) 34 (87.18)
CK-7 0.006 1.000
 Negative 19 (5.79) 3 (1.27) 21 (3.94) 1 (3.13)
 Positive 309 (94.21) 234 (98.73) 512 (96.06) 31 (96.88)
Ki67 0.083 0.528
 Negative 37 (28.03) 28 (40.00) 60 (31.58) 5 (41.67)
 Positive 95 (71.97) 42 (60.00) 130 (68.42) 7 (58.33)

Values presented are n (%) unless otherwise noted

EGFR epidermal growth factor receptor; ALK anaplastic lymphoma kinase; AFP alpha fetoprotein; CEA carcinoembryonic antigen; CA carbohydrate antigen; FERR ferritin; PSA prostate specific antigen; FPSA free prostate specific antigen; SCC squamous cell carcinoma antigen; CYFRA 21-1 soluble fragment of cytokeratin 19; NSE neuron-specific enolase; TTF-1 thyroid transcription factor-1; CK-7 cytokeratin-7